Med. praxi. 2010;7(4):177-182

Systemic lupus erythematosus - a prototype of the autoimmune disorder, diagnosis, therapy

doc.MUDr.Pavel Horák, CSc., MUDr.Martina Skácelová, MUDr.Andrea Smržová, doc.MUDr.Josef Zadražil, CSc., MUDr.Hana Ciferská, MUDr.Tomáš Tichý, MUDr.Zuzana Heřmanová, Mgr.Kateřina Langová, MUDr.Martin Žurek
III. interní klinika, FN a LF UP Olomouc
Oddělení klinické imunologie, FN a LF UP Olomouc

Autoimmunity is a process, in which some parts of the immune systém recognize the own organizm and cause its damage. Systemic

lupus erythematosus is a prototype of the autoimmune organ non-specific disorder. It affects predominantly young females. Lupus is

highly heteregenous disease with various clinical manifestations and prognosis. The correct identification of the autoimmune clinical

symptoms, testing for auto-antibodies, assessment of disease activity and organ damage play the crucial role in the SLE diagnosis.

The therapy of the severe forms of SLE should be coordinated by a specialist. The axis of the SLE therapy comprises glucocorticoids,

antimalarials, immunosupressive and, in the case of antiphospholipid syndrome, antikoagulant drugs. In recent year new drugs for

severe or moderate lupus are emerging and tested in clinical trials.

Keywords: autoimmunity, systemic lupus erythematosus (SLE), diagnosis, auto-antibodies, therapy

Published: May 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Horák P, Skácelová M, Smržová A, Zadražil J, Ciferská H, Tichý T, et al.. Systemic lupus erythematosus - a prototype of the autoimmune disorder, diagnosis, therapy. Med. praxi. 2010;7(4):177-182.
Download citation

References

  1. Dostál C. Klinické projevy SLE. In: Dostál C, Vencovský J, et al. Systémový lupus erythematosus. Medprint 1997: 79-166.
  2. Weening JJ, D´Agati, WD, Schwartz MM, et at. Classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15: 241-250. Go to original source... Go to PubMed...
  3. Gladman DD, Urowitz MB. SLE-Clinical Features. In: Klippel JH, Dieppe PA, eds. Rheumatology. Mosby 1995; 6.22-6.23.
  4. Egner W. The use of laboratory tests in the diagnosis of SLE. J Clin Pathol 2000; 53: 424-432. Go to original source... Go to PubMed...
  5. Isenberg DA, Garton M, Reichlin MW, et al. Long term follow-up of autoantibody profiles in black female lupus patients and clinical comparison with Caucasian and Asian patients. Br J Rheumatol 1997; 36: 229-233. Go to original source... Go to PubMed...
  6. ter Borg EJ, Horst G, Hummel EJ, et al. Measurement of increase in anti-double-standed DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long term, prospective study. Arthritis Rheum 1990; 33: 634-643. Go to original source... Go to PubMed...
  7. Horák P, Heřmanová Z, Zadražil J, et al. C1q complement component and antibodies reflect SLE activity and kidney involvement. Clinical Rheumatology, 2006; 25: 532-536. Go to original source... Go to PubMed...
  8. Vencovský J. Autoprotilátky u systémového lupus erytematodes. In: Dostál C, Vencovský J, et al. Systémový lupus erythematosus. Medprint 1997: 38-56.
  9. Walport MJ. Complement and systemic lupus erythematosus. Arthritis Res 2002; 4(Suppl 3): 279-293. Go to original source... Go to PubMed...
  10. Shur PH, Wallace D. Overview of the therapy and prognosis of systemic lupus erythematosus in adults. UpToDate 2009; online, This topic last updated: září 28, 2009.
  11. Nossent HC, Koldingsnes W. Long-term efficacy of azathioprine treatment for proliferative lupus nephritis. Rheumatology 2000; 39: 969-974. Go to original source... Go to PubMed...
  12. Boumpas D, Barez S, Klippel J, et al. Intermittent cyclophosphamide for the treatment of autoimmune thrompocytopenia in systemic lupus erythematosus. Ann Int Med. 1990; 112: 674-677. Go to original source... Go to PubMed...
  13. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20: 1103-1112. Go to original source... Go to PubMed...
  14. Falk RJ, Schur P, Appel GA. Treatment of resistant or relapsing difusse or focal proliferative lupus nephritis. UpToDate 2009; online, This topic last updated: červenec 2, 2009.
  15. Walsh M, James M, Jayne D, Tonelli M, et al. Mycophenolate mofetil for induction therapy of lupus nephritis: A systematic review and meta-analysis. Clin J Am Soc Nephrol 2007; 2: 968-975. Go to original source... Go to PubMed...
  16. Melander C, Sallee M, Trolliet P, et al. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol 2009; 4: 579-587. Go to original source... Go to PubMed...
  17. Boletis JN, Marinaki S, Skalioti C, et al. Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long term prospective study. Nephrology Dialysis Transplantation 2009; 24(7): 2157-2160. Go to original source... Go to PubMed...
  18. Lewis EJ, Hunsicker LG, Lan SP, et al. A controlled trial of plasmapheresis therapy during severe lupus nephritis. N England J Med 1992; 326: 1373-1379. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.